Analyst Tim Anderson from Bank of America Securities reiterated a Hold rating on Pfizer (PFE – Research Report) and keeping the price target at ...
Pfizer Inc. got a reprieve — at least for now — in its battle with activist investor Starboard Value LP, according to people ...
The pharmaceutical giant Pfizer will pay nearly $60 million to resolve charges that a company it acquired paid kickbacks so ...
Pfizer’s subsidiary Biohaven has agreed to a settlement nearing $60 million to resolve allegations of false claims related to ...
Starboard last year took a $1 billion stake in Pfizer, looking to turn the pharma around after alleged severe shortcomings by ...
Over the years, the U.S. Department of Justice (DOJ) has taken a host of drugmakers to task over alleged kickback payments ...
Pharmaceutical Technology on MSN3d
Pfizer settles Biohaven kickback claims case for $59.7mBiohaven, acquired by Pfizer in 2022, allegedly took doctors to high-end restaurants and paid speaker honoraria for ...
Pfizer subsidiary Biohaven allegedly gave physicians speaker honoraria and meals at high-end restaurants to induce them to prescribe Nurtec.
Following a tough opening salvo from Starboard Value last fall, Pfizer is getting a chance to catch its breath in the ...
Pfizer will pay $59.7 million to resolve charges that a company it acquired defrauded Medicare and other healthcare programs ...
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...
Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback